Bretisilocin, also known as GM-2505 or 5-fluoro-N-methyl-N-ethyltryptamine, is a serotonergic psychedelic tryptamine analogue under development as a treatment for major depressive disorder. It's a 5-fluorinated derivative of methylethyltryptamine (MET) and an analogue of dimethyltryptamine (DMT). The administration route for Bretisilocin is intravenous infusion.
2022: First Description in Literature
In 2022, Bretisilocin was first described in the scientific literature.
June 2025: Phase 2 Clinical Trials
In June 2025, Bretisilocin is in phase 2 clinical trials for the treatment of major depressive disorder, and a phase 2a trial has been completed, with the efficacy and safety data released.
August 2025: Acquisition by AbbVie
In August 2025, AbbVie acquired Bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion.
Trending
4 hours ago Ann Li Faces Alina Korneeva in Upcoming WTA Athens Tennis Match
4 hours ago Ian Baker-Finch Champions Global Golf Talent to Compete in New Zealand and Australia
5 hours ago Alexander Bublik Faces Quentin Halys at ATP Swiss Open in Gstaad
5 hours ago Rocket Lab Successfully Tests Powerful New Archimedes Engine for Neutron Launcher
5 hours ago Analyzing Potential Investment Trends and Market Performance of the VanEck Semiconductor ETF (SMH)
5 hours ago Drake Maye Recognized as Top NFL Quarterback and Future Football Star
Popular
Lindsey Graham is a prominent American politician serving as the...
Mitch McConnell is a prominent American politician and the longest-serving...
Cristiano Ronaldo widely considered one of the greatest footballers captains...
Elon Musk is a visionary entrepreneur and engineer known for...
Candace Owens is an American conservative political commentator author and...
Bernie Sanders is a prominent American politician and the senior...